Individualized therapies: CBER director discusses challenges, regulatory approach
The FDA’s Center for Biologics Evaluation and Research (CBER) is looking for ways to facilitate the development of more products …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
